Anna Maria Grazia Gelli

Dr. Anna Maria Grazia Gelli


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
FRfrancesca romano
francesca romano
VBValentina Becherucci
Valentina Becherucci
SMSara Ciullini Mannurita
Sara Ciullini Mannurita
EREdda Russo
Edda Russo
AMAlessandra Mongia
Alessandra Mongia
FBFRANCESCA BRUGNOLO
FRANCESCA BRUGNOLO
Background: The Sysmex XN series (XN-1000 and XN-9100, Sysmex Corporation, Kobe, Japan) represents a latest-generation automated hematology platform integrating fluorescence-based technologies and multi-channel analysis (WDF and WPC) to improve leukocyte characterization. This study aimed to evaluate the performance of the Sysmex XN series in detecting leukocyte abnormalities flagged during routine complete blood count analysis in a large cohort of healthy donors, using morphological assessment and flow cytometry as confirmatory methods. Methods: Approximately 8000 healthy blood donors from the AOU Meyer Transfusion Centre were evaluated between 2021 and 2024. All samples underwent CBC analysis using the XN-1000 and XN-9100 analyzers with the WDF channel. Samples showing WBC-related flags were subjected to reflex testing with the WPC channel, followed by digital blood smear review using the DI-60 system (CellaVision, Lund, Sweden) and flow cytometric immunophenotyping. Results: WDF flags for “blasts/abnormal lymphocytes” were identified in 23 samples. Two samples were negative on WPC analysis as well as on morphological and flow cytometric evaluation. Among the remaining cases, WPC analysis identified flags for abnormal lymphocytes, atypical lymphocytes, or blasts, which were variably associated with reactive changes, transient immune activation, or clonal lymphoproliferative conditions. In one donor, monoclonal B-cell lymphocytosis was diagnosed by flow cytometry. Overall, reactive morphological features confirmed by flow cytometry were observed in approximately 50% of flagged cases. Conclusions: WPC analysis provides relevant additional diagnostic information and demonstrates higher specificity compared with the WDF channel alone; however, it does not fully resolve all instrument-generated flags, confirming the essential role of morphological assessment. Interestingly, the frequent occurrence of inflammatory profiles in recently vaccinated donors suggests that transient immune activation may influence leukocyte flagging. Larger studies are warranted to further investigate this association and to optimize the diagnostic performance of the WPC channel in donor screening.

24 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TBTiziana Biagioli
Tiziana Biagioli
LLLuisa Lanzilao
Luisa Lanzilao
FRfrancesca romano
francesca romano
SMSara Ciullini Mannurita
Sara Ciullini Mannurita
VBValentina Becherucci
Valentina Becherucci
EREdda Russo
Edda Russo
Serum protein electrophoresis (SPE) remains a central laboratory method for the detection and characterization of monoclonal gammopathies and other dysproteinemic patterns. Despite substantial analytical automation, interpretation still relies largely on graphical representation and expert visual assessment, making low-amplitude or borderline abnormalities particularly challenging. Artificial intelligence (AI), including machine-learning (ML) and deep-learning (DL) approaches, has increasingly been applied to SPE, with high performance reported for automated recognition of established abnormalities, particularly M-proteins, i.e., monoclonal immunoglobulins or immunoglobulin fragments produced by clonal plasma cells. However, most models have been developed against predefined diagnostic targets and evaluated using expert interpretation, immunofixation, or immunotyping as reference standards. Improved recognition of known abnormalities should therefore not be equated with discovery of additional clinically meaningful information. Modern electrophoretic platforms generate machine-readable numerical signals that may preserve features not explicitly considered during routine graphical interpretation. This creates the possibility of extending AI-assisted SPE from conventional pattern recognition toward detection of low-amplitude, distributed, or sub-visual signal characteristics. Yet current literature has focused predominantly on algorithmic performance, while the validation pathway required to determine whether additional AI-detected features are biologically meaningful and clinically actionable remains insufficiently defined. Evidence is strongest for automated M-protein recognition, including low-amplitude abnormalities, whereas non-canonical systemic patterns, longitudinal signal analysis, and AI-assisted decomposition of therapeutic monoclonal antibody interference remain exploratory. This critical review addresses this translational gap by evaluating AI applications according to the nature of detected information, strength of supporting evidence, and proximity to clinical implementation. We propose a translational framework in which additional AI-detected electrophoretic features progress through analytical validity, biological validity, clinical validity, and clinical utility before being considered actionable laboratory information.

19 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
TBTiziana Biagioli
Tiziana Biagioli
LLLuisa Lanzilao
Luisa Lanzilao
FRfrancesca romano
francesca romano
SMSara Ciullini Mannurita
Sara Ciullini Mannurita
VBValentina Becherucci
Valentina Becherucci
EREdda Russo
Edda Russo
Serum protein electrophoresis (SPE) remains a central laboratory method for the detection and characterization of monoclonal gammopathies and other dysproteinemic patterns. Despite substantial analytical automation, interpretation still relies largely on graphical representation and expert visual assessment, making low-amplitude or borderline abnormalities particularly challenging. Artificial intelligence (AI), including machine-learning (ML) and deep-learning (DL) approaches, has increasingly been applied to SPE, with high performance reported for automated recognition of established abnormalities, particularly M-proteins, i.e., monoclonal immunoglobulins or immunoglobulin fragments produced by clonal plasma cells. However, most models have been developed against predefined diagnostic targets and evaluated using expert interpretation, immunofixation, or immunotyping as reference standards. Improved recognition of known abnormalities should therefore not be equated with discovery of additional clinically meaningful information. Modern electrophoretic platforms generate machine-readable numerical signals that may preserve features not explicitly considered during routine graphical interpretation. This creates the possibility of extending AI-assisted SPE from conventional pattern recognition toward detection of low-amplitude, distributed, or sub-visual signal characteristics. Yet current literature has focused predominantly on algorithmic performance, while the validation pathway required to determine whether additional AI-detected features are biologically meaningful and clinically actionable remains insufficiently defined. Evidence is strongest for automated M-protein recognition, including low-amplitude abnormalities, whereas non-canonical systemic patterns, longitudinal signal analysis, and AI-assisted decomposition of therapeutic monoclonal antibody interference remain exploratory. This critical review addresses this translational gap by evaluating AI applications according to the nature of detected information, strength of supporting evidence, and proximity to clinical implementation. We propose a translational framework addressing four complementary domains: analytical validity, biological validity, clinical validity, and clinical utility. The evidence required in each domain depends on the intended claim and clinical use.